Abstract:Previous studies have demonstrated that pioglitazone (Piog), a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, inhibits ischemia-induced brain injury. Piog has also been shown to exert anti-inflammatory effects by attenuation of nuclear factor-κB (NF-κB) activation after myocardial ischemia/reperfusion injury. Because NF-κB is known to play a major role in the pathophysiology of brain ischemia, the present study was undertaken to elucidate whether pioglitazone attenuates ischemic neuronal damage through PPARγ-mediated suppression of NF-κB apoptotic signaling pathway. Permanent middle cerebral artery occlusion (pMCAO) model was induced by using an intraluminal filament technique in rats. Piog was administrated i.p. twice (24 h before and at the time of ischemia insult) or once (10 min after ischemia). The neuroprotection of Piog was analyzed by assessing neurological deficits, infarction volume and morphological changes. The inhibition of NF-κB signaling pathway by Piog was evaluated by detecting the nuclear translocation of NF-κB p65 with immunohistochemistry and its target gene p53 by real-time PCR, and the expression of phospholated NF-κB p65 (p- NF-κB p65) in primary cultured neurons and the protein levels of IκBα and p-ERK in the ischemic cortex or striatum with Western blotting analysis. The contribution of a PPARγ mechanism to Piog's inhibitory effects on NF-κB and neuroprotection was evaluated by pretreatment with the PPARγ irreversible antagonist GW9662. In vitro ischemia in cultured primary neurons was induced by the oxygen-glucose deprivation (OGD) and the protective effect of Piog on cultured neurons was measured by lactate dehydrogenase (LDH) assay. Piog (0.5, 1, 2 mg/kg) reduced infarction volume, and improved morphological changes and motor deficits. Piog markedly up-regulated the protein levels of IκBα or p-ERK 6 h or 12 h after ischemia. Piog reduced the nuclear translocation of NF-κB p65 in the ischemic cortical cells and repressed the expression of p53 12 h after ischemia. Pre-treatment with GW9662 blocked Piog-elicited reduction in infarction volume, the increase in protein levels of IκBα and p-ERK, the reduction in the nuclear translocation of NF-κB subunit p65 and the repression of p53 mRNA expression. In addition, Piog attenuated the OGD-induced neuronal damage and inhibited the OGD-induced increases in p- NF-κB p65 in neurons. The present findings suggest that Piog's neuroprotection appears to be associated with PPARγ-mediated suppression of NF-κB signaling pathway.

Effect of Pioglitazone on Neuropathic Pain and Spinal Expression of TLR-4 and Cytokines.

Repeated administration of pioglitazone attenuates development of hyperalgesia in a rat model of neuropathic pain.

Effect of sciatic nerve pulsed radiofrequency glial activation levels in spinal dorsal horn in chronic constriction injury rat models and its analgesia effect

Pulsed Radiofrequency to the Dorsal Root Ganglion or the Sciatic Nerve Reduces Neuropathic Pain Behavior, Decreases Peripheral Pro-Inflammatory Cytokines and Spinal Β-Catenin in Chronic Constriction Injury Rats

Effect of PPARγ on the Analgesic Effects of Pioglitazone

Spinal neuroimmune activation inhibited by repeated administration of pioglitazone in rats after L5 spinal nerve transection.

The Analgesic Effects of Pioglitazone in the Bone Cancer Pain Rats Via Regulating the PPARγ/PTEN/mTOR Signaling Pathway in the Spinal Dorsal Horn.

Neuroprotective Effects of Pioglitazone in a Rat Model of Permanent Focal Cerebral Ischemia Are Associated with Peroxisome Proliferator-Activated Receptor Gamma-Mediated Suppression of Nuclear Factor-Κb Signaling Pathway

Effect and Mechanism of Inhibition of PI3K/Akt/mTOR Signal Pathway on Chronic Neuropathic Pain and Spinal Microglia in a Rat Model of Chronic Constriction Injury.

Peroxisome Proliferator-Activated Receptor Gamma Agonist Pioglitazone Alleviates Hemorrhage-Induced Thalamic Pain and Neuroinflammation.

Pioglitazone, Ppar Gamma Agonist, Attenuates Experimental Autoimmune Neuritis

PPAR Γ Prevents Neuropathic Pain by Down-Regulating CX3CR1 and Attenuating M1 Activation of Microglia in the Spinal Cord of Rats Using a Sciatic Chronic Constriction Injury Model.

Pioglitazone, PPARγ Agonist, Attenuates Experimental Autoimmune Neuritis

PPARγ activation mitigates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of Nrf2/HO-1 signaling pathway

Pioglitazone Ameliorates Retinal Ischemia/Reperfusion Injury Via Suppressing Nlrp3 Inflammasome Activities

Pioglitazone Attenuates Experimental Colitis-Associated Hyperalgesia Through Improving the Intestinal Barrier Dysfunction

Effect of pioglitazone on nerves of rats following traumatic brain injury

[Pioglitazone Decreases the Levels of Inflammatory Cytokines in SD Rats with Traumatic Brain Injury Via Up-Regulating PPARγ].

Effects of Peroxisome Proliferator-Activated Receptor Gamma Agonist Pioglitazone on Neurocyte Apoptosis and Expression of ICAM-1 after Traumatic Brain Injury

Blockade of P2X4 Receptors Inhibits Neuropathic Pain-Related Behavior by Preventing MMP-9 Activation and, Consequently, Pronociceptive Interleukin Release in a Rat Model

Tetramethylpyrazine and Astragaloside IV have synergistic effects against spinal cord injury-induced neuropathic pain via the OIP5-AS1/miR-34a/Sirt1/NF-κB axis